<DOC>
	<DOCNO>NCT01550848</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity Abraxane combine Gemcitabine patient metastatic breast cancer .</brief_summary>
	<brief_title>A Phase II Study Abraxane Gemcitabine Combination Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>This study investigate efficacy toxicity Abraxane combine Gemcitabine patient metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Female 18 70 year old ; Patients histologic prove metastatic breast cancer , unsuitable treat surgery ; ECOG ( Eastern Cooperative Oncology Group ) 0~1 ; Normal function heart , liver , renal bone marrow : WBC≥3.5×109/L；Hb≥90 g/L；plt≥100×109/L ; Got ICF ( Informed Consent Form ) enrollment ; Life expectancy 12 week Pregnant breastfeed woman positive serum pregnancy test ; Uncontrolled brain metastasis . Patients brain metastasis must locally treated disease must stable least one month time enrol ; Participation investigational drug study within 4 week precede treatment start ; Concurrent malignancy sit previous cancer within last 5 year , exception adequately treat situ carcinoma cervix uteri basal squamous cell carcinoma skin contralateral breast cancer ; Serious uncontrolled intercurrent infection ; Poor compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>